Paul Carpenter

Appointments and Affiliations

 
 
Fred Hutchinson Cancer Research Center
Clinical Research Division
Member
University of Washington
School of Medicine
Pediatrics
Professor, Appointed: 2013
Professional Headshot of Paul  Carpenter

Mailing Address

1100 Fairview Avenue North
D5-290
Seattle, Washington 98109
United States

Degrees

MBBS, University of Sydney, Australia, Medicine and Surgery, 1988.
B.S., University of Sydney, Australia, Medicine, 1985.

Research Interests

Allogeneic hematologic cell transplant (HCT) is a curative strategy for many life-threatening conditions, however, graft-versus-host disease (GVHD) remains a major, potentially lethal, complication. Dr Carpenter's research interest and direction is aimed toward improving the therapy of graft-versus-host disease. Pre-clinical work and a Phase I clinical trial have so far explored the use of novel humanized anti-CD3 monoclonal antibodies as a means of manipulating pathogenic T cell responses.

Clinical Expertise and Interests include:
1) Acute GVHD
2) Chronic GVHD
3) Long-term follow-up of HCT survivors

Additional Experience

1. Histiocytic Disorders of Childhood, Langerhans Cell Histiocytosis and Familial Hemophagocytic Lymphohistiocytosis
2. Hematopoeitic Cell Transplantation for Osteopetrosis

Future Research

Ongoing clinical research endeavours involves exploration of new therapies for the treatment of acute and chronic graft-versus-host disease (GVHD).

Building on results of pre-clinical studies (Carpenter et al, J. Immunology, 2001) and on the encouraging results of a phase I trial of humanized anti-CD3 monoclonal antibody, visilizumab in steroid-refractory acute GVHD (Carpenter et al, Blood, 2002) two national multicenter trials are currently open. One trial is further exploring the efficacy of visilizumab in acute steroid-refractory GVHD. The other trial aims to determine the safety and preliminary effiacy of visilizumab when administered to patients as initial therapy for severe acute GVHD instead of a standard glucocorticoid therapy.

Based onclinical studies that show that sirolimus is an effective immunosuppressive agent in solid organ transplantation and that sirolimus might facilitate transplantation tolerance, a Phase II trial of sirolimus for patients who have failed first-line (or other) therapies for chronic GVHD is currently underway.

Memberships

American Society for Clinical Oncology
American Society of Hematology
Royal Australasian College of Physicians

Honors and Awards

1999-2002, Research Fellow, The Leukemia and Lymphoma Society
1998-1999, Young Investigator Award, American Society of Clinical Oncology, Tolerance to Stem Cell Grafts By Targeting the T Cell Receptor

Recent Publications

2014
2013
Hitzler, JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT et al..  2013.  Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
2012
Inamoto, Y, Martin PJ, Chai X, Jagasia M, Palmer J, Pidala J, Cutler C, Pavletic SZ, Arora M, Jacobsohn D et al..  2012.  Clinical Benefit of Response in Chronic Graft-versus-Host Disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(10):1517-24. Abstract
Martin, PJ, Inamoto Y, Flowers MED, Carpenter PA.  2012.  Secondary Treatment of Acute Graft-versus-Host Disease: A Critical Review.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(7):982-8. Abstract
Carpenter, PA, Meshinchi S, Davies SM.  2012.  Transplantation for AML in children.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(1 Suppl):S33-9.
2011